This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.


Studying New Antidepressants: If There Were a Light at the End of the Tunnel, Could We See It?

Michael E. Thase, MD

Published: February 1, 2002

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

The availability of so many newer antidepressants necessitatesthat clinicians make daily judgments about the relative utility of these medications. Traditionally, it hasbeen assumed that antidepressants that have passed the reviewprocess of the U.S. Food and Drug Administration(FDA) are (more or less) comparably effective.1 If treatmentoptions are truly comparably effective, then factorssuch as convenience, tolerability, safety, and cost are typicallyused to determine which medications are selectedfirst, second, and third in a sequence of choices.2‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 63

Quick Links: